Dr reddys laboratories News: Dr reddys laboratories Latest News, Dr reddys laboratories Today news, Dr reddys laboratories Breaking News

Fresenius Kabi will handle exclusive commercialisation of the product in the United States under an existing agreement between the two firms.

Dr Reddy’s gets US FDA approval for cancer biosimilar Rituximab, enters US market

Dr Reddy’s Laboratories receives US FDA approval for its rituximab biosimilar, marking a key entry into the US market and…

August 3, 2026 10:31 IST

Cipla vs Dr Reddy Q1 FY27 earnings and US pipeline comparison

Cipla Vs Dr. Reddy’s: Which pharma giant offers better risk-reward as spotlight shifts to US pipeline

Cipla and Dr. Reddy’s entered FY27 on different trajectories. While Cipla posted record quarterly revenue backed by respiratory growth, Dr.…

Updated: July 29, 2026 13:08 IST

A financial trading screen showing Dr. Reddy’s Laboratories' stock price declining 7% to a 52-week low on the NSE. The interface overlays key Q1FY27 financial metrics, including a 69% YoY drop in net profit, a ₹240 crore Semaglutide API inventory provision, and EBITDA margin contraction to 10%.

Dr Reddy’s slides to 52-week low: Brokerages slash price target on Semaglutide API, Middle East concerns

Dr Reddy’s hits a 52-week low after weak Q1 earnings, Semaglutide API issues and Middle East costs trigger target cuts;…

July 23, 2026 10:53 IST

Dr Reddy’s Q1FY27: Net Profit declines 69% YoY, impacted by Rs 239 crore semaglutide provisions

Dr Reddy’s Q1FY27 net profit fell 69% YoY to Rs 443.5 crore, hit by Rs 239.7 crore semaglutide API provisions;…

Updated: July 22, 2026 17:14 IST

A financial trading terminal displaying the Nifty Pharma Index drop alongside a visual timeline breakdown of Donald Trump's phased tariff policy on generic drug imports—showing 0% duty until August 2028, 100% in 2028–2029, and 200% from August 2029 onward.

Pharma stocks fall after Trump’s 200% tariff announcement for generic imports: Experts decode what it means

Track pharma stocks as Trump’s phased US tariff plan hits sentiment, though analysts say India’s cost edge may cushion generic…

July 22, 2026 10:36 IST

A sophisticated financial analytics dashboard displaying a curated grid of top institutional stock picks. The interactive terminal lists clear upward projection indicators alongside data rows mapping a 47% upside target for Kalyan Jewellers, a ₹505 target for Indus Towers, and a resilient 24% AUM expansion tracker for Bajaj Finance.

Top 10 stocks rated ‘Buy’ this week: Brokerages project 10% to 47% returns

Explore 10 brokerage ‘Buy’ stock picks, from Kalyan Jewellers to Dr Reddy’s, with projected upsides of 10%–47% amid weak markets.

July 11, 2026 10:58 IST

Close-up of a modern corporate biotechnology research screen mapping out localized manufacturing compliance data. Interactive panels track the progress of three upcoming fresh validation batches alongside long-term strategic EPS forecasts pointing toward Rs 78 driven by the Abatacept opportunity.

Dr Reddy’s: JM Financial decodes the semaglutide supply delay and the hidden catalyst set to drive the stock higher

JM Financial keeps Dr Reddy’s at Buy despite semaglutide delay, seeing 23% upside and an FY28 Abatacept catalyst—track the stock.

July 10, 2026 14:29 IST

Dr Reddy’s, Sun Pharma, Divi’s go ex-dividend in July; check record dates and dividend payouts

Dr Reddy’s, Sun Pharma, Divi’s turn ex-dividend in July: Check full list and record dates

Sun Pharma, Dr Reddy’s, Zydus and Divi’s Labs turn ex-dividend in July as pharma stocks near highs; check record dates…

July 3, 2026 15:33 IST

Close-up of a modern corporate financial terminal comparing consensus estimates with Nomura’s forward projections showing a 13% earnings premium alongside a green stock ticker loop for DRREDDY.

Dr Reddy’s: Why Nomura sees 35% upside potential after strategic consumer health pivot

Nomura sees 35% upside for Dr Reddy’s as it pivots to branded consumer health; check if now is the time…

June 23, 2026 12:22 IST

Pharma dividend watch: Abbott India, Torrent Pharma, Sun Pharma among 7 stocks with upcoming record dates

Pharma stocks including Abbott India, Sun Pharma, Torrent Pharma, Cipla and Divi’s Laboratories are in focus after announcing FY26 dividends…

Updated: May 25, 2026 07:55 IST

An infographic comparing Nomura’s target prices for Dr. Reddy’s, Cipla, and Crompton Greaves, highlighting growth drivers like GLP-1 drug traction and ECD market expansion.

Cipla, Dr Reddy’s Lab, Crompton Greaves: Nomura’s top picks with 17% to 26% upside potential

Nomura sees up to 26% upside in Cipla, Dr Reddy’s Lab, and Crompton Greaves—discover why these stocks are top picks…

Updated: May 14, 2026 15:29 IST

HSBC India Underweight rating April 2026 stock market impact

Cipla to Sun Pharma: Nomura rates these 6 pharma stocks, riding the GLP-1 wave, ‘Buy’

The Indian Pharmaceutical Market (IPM) grew 10.1% year-on-year in March 2026, according to the report. Pricing contributed 5.5% to growth,…

Updated: April 15, 2026 15:21 IST

A technical stock market dashboard showing the FII long-short ratio at 16.8, with Sun Pharma and Tata Steel charts highlighting "Doji" and "Reversal" candlestick patterns near key support levels.

Monday Watchlist: Vedanta, Tata Steel, and 7 other stocks to watch – Small-caps show strength

Monday watchlist, April 05: Track Vedanta, Tata Steel, and top small-caps as technical trends signal possible short-term reversals—review market moves…

April 6, 2026 05:30 IST

₹1,000 cr to ₹5,000 cr: 3 pharma stocks to watch for India’s GLP-1 explosion by 2030

A ₹1,000 crore market is set to grow 5x to ₹5,000 crore by 2030 as prices drop 40–50% post patent…

March 31, 2026 05:27 IST

The brokerage believes semaglutide could become a meaningful growth driver for India’s pharma sector, but as more players enter and pricing pressure builds, execution, pricing strategy and distribution strength will determine long-term winners.

Alkem, Zydus Life: Nomura’s top picks to bet on Rs 12,000 crore generic Semaglutide opportunity

Nomura has a ‘Buy’ rating on Zydus Lifesciences, with the stock at Rs 891 and a target price of Rs…

March 23, 2026 14:55 IST

Dr Reddy’s launches ‘Obeda’ semaglutide injection

Dr Reddy’s on ‘Obeda’ launch: In step to democratize access to advanced therapy

Dr. Reddy’s Laboratories has launched ‘Obeda’, an injectable semaglutide therapy for diabetes and weight management in India.

March 21, 2026 21:09 IST

semaglutide india pharma stocks ozempic patent expiry

Sun Pharma to Cipla: 7 pharma stocks gear up for Rs 5,000 cr semaglutide opportunity after patent expiry

Ozempic patent expiry has triggered a fresh pharma race in India. Sun Pharma, Cipla, and Dr Reddy’s are among 7…

March 20, 2026 17:58 IST

Nippon India Small Cap Fund portfolio strategy returns MCX HDFC Bank

Nuvama ‘Overweight’ 8 stocks: Why Reliance, HDFC Bank, Infosys are top picks – Check full list

Nuvama turns selective in a risky market, backing Reliance, HDFC Bank and Infosys while flagging metals and autos as overvalued…

March 19, 2026 08:32 IST

Dr Reddy's Laboratories

Related News

Trending Topics